Detection Rate of (18)F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis.

Details

Serval ID
serval:BIB_21D350726EDC
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Detection Rate of (18)F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis.
Journal
Cancers
Author(s)
Treglia G., Annunziata S., Pizzuto D.A., Giovanella L., Prior J.O., Ceriani L.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Publication state
Published
Issued date
23/05/2019
Peer-reviewed
Oui
Volume
11
Number
5
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Background: The use of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for biochemical recurrent prostate cancer (BRPCa) is increasing worldwide. Recently, <sup>18</sup> F-labeled PSMA agents have become available. We performed a systematic review and meta-analysis regarding the detection rate (DR) of <sup>18</sup> F-labeled PSMA PET/CT in BRPCa to provide evidence-based data in this setting. Methods: A comprehensive literature search of PubMed/MEDLINE, EMBASE, and Cochrane Library databases through 23 April 2019 was performed. Pooled DR was calculated on a per-patient basis, with pooled proportion and 95% confidence interval (95% CI). Furthermore, pooled DR of <sup>18</sup> F-PSMA PET/CT using different cut-off values of prostate-specific antigen (PSA) was obtained. Results: Six articles (645 patients) were included in the meta-analysis. The pooled DR of <sup>18</sup> F-labeled PSMA PET/CT in BRPCa was 81% (95% CI: 71-88%). The pooled DR was 86% for PSA ≥ 0.5 ng/mL (95% CI: 78-93%) and 49% for PSA < 0.5 ng/mL (95% CI: 23-74%). Statistical heterogeneity was found. Conclusions: <sup>18</sup> F-labeled PSMA PET/CT demonstrated a good DR in BRPCa. DR of <sup>18</sup> F-labeled PSMA PET/CT is related to PSA values with significant lower DR in patients with PSA < 0.5 ng/mL. Prospective multicentric trials are needed to confirm these findings.
Keywords
DCFBC, DCFPyL, PET, PSMA, PSMA-1007, prostate
Pubmed
Web of science
Open Access
Yes
Create date
14/06/2019 17:55
Last modification date
11/09/2019 11:50
Usage data